Learn More
Powering A
New Era Of
RNA Therapeutics
Opus aims to unlock existing limitations within the drug delivery space by enabling safer chronic re-dose / single dose therapeutics.
Read The Paper ↗
the problem
LNPs are one of the most promising delivery modalities, but their inherent Toxicity has led to failed trials, clinical setbacks, and tradeoffs. Other delivery modalities also face tradeoffs in cargo, safety, efficacy, targeting, and chronic/ single dose constraints.
Our Technology
A New Gold Standard
- 01
LNPs trigger immune-activating pathways. Opus has created a new class of LNPs that bypass these immune pathways, enabling safe, repeat/ single-dose therapies without compromising expression.
- 02
Opus LNPs enable treatment of both chronic re-dose/ single dose RNA therapies, areas currently limited by immunogenicity.
- 03
Opus aims to enable not only intravenous (IV) administration of its LNPs, but also more patient-friendly routes such as subcutaneous (SC) injection.
Our story
A New Approach To Non-Viral Delivery
Opus was founded out of the Murthy Lab at the Innovative Genomics Institute, UC Berkeley. Our team of scientists specializes in developing novel drug delivery systems, with a focus on advancing RNA therapeutics.
